Pfizer hires ex-FDA drug chief

Pfizer hires ex-FDA drug chief as top doctor
The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until January,
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
Ex-CDER chief Patrizia Cavazzoni becomes Pfizer’s chief medical officer
After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. | After leaving the FDA,
Pfizer Names Former FDA Drug Chief as Top Doctor
Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.
Pfizer names former FDA director as chief medical officer
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory and drug safety operations.
Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency
HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.
STAT4h
Turbulence at the FDA & bluebird Bio’s sale
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...
BioSpace2d
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
Peninsula drugmaker nails heart failure drug launch in battle with Big Pharma
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
STAT4d
Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
FiercePharma7d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
BioPharma Dive4d
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Pharmaceutical Technology1d
Pfizer’s bet on gene therapies in haemophilia has been a bust
Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients and physicians.
FDA's Top Regulator Just Took a Senior Job at Pfizer
Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big Pharma over vulnerable patients. She'll fit right in with Scott Gottlieb.